|
|
Books > Medicine > Other branches of medicine > Pharmacology > General
Dendrimer-Based Nanotherapeutics delivers a comprehensive resource
on the use of dendrimer-based drug delivery. Advances in the
application of nanotechnology in medicine have given rise to
multifunctional smart nanocarriers that can be engineered with
tunable physicochemical characteristics to deliver one or more
therapeutic agent(s) safely and selectively to cancer cells,
including intracellular organelle-specific targeting. This book
compiles the contribution of dendrimers in the field of
nanotechnology to aid researchers in exploring dendrimers in the
field of drug delivery and related applications. This book covers
the history of the area to the most recent research. The starting
chapter covers detailed information about basic properties about
dendrimers i.e. properties, nomenclature, synthesis methods, types,
characterization of dendrimers, safety and toxicity issues of
dendrimers. Further chapters discuss the most recent advancements
in the field of dendrimer i.e. dendrimer-drug conjugates, PEGylated
dendrimer, dendrimer surface engineering, dendrimer hybrids,
dendrimers as solubility enhancement, in targeting and delivery of
drugs, as photodynamic therapy, in tissue engineering, as imaging
contrast agents, as antimicrobial agents, advances in targeted
dendrimers for cancer therapy and future considerations of
dendrimers. Dendrimer-Based Nanotherapeutics will help the readers
to understand the most recent progress in the field of
dendrimer-based research, suitable for pharmaceutical scientists,
advanced students, and those working in related healthcare fields.
Engineering Technologies and Clinical Translation: Volume 3:
Delivery Strategies and Engineering Technologies in Cancer
Immunotherapy examines the challenges of delivering immuno-oncology
therapies, focusing specifically on the development of solutions
for drug delivery and its clinical outcomes. Immuno-oncology (IO)
is a growing field of medicine at the interface of immunology and
cancer biology leading to development of novel therapeutic
approaches, such as chimeric antigen receptor T-cell (CAR-T) and
immune checkpoint blockade antibodies, that are clinically approved
approaches for cancer therapy. Although currently approved IO
approaches have shown tremendous promise for select types of
cancers, broad application of IO strategies could even further
improve the clinical success, especially for diseases such as
pancreatic cancer, brain tumors where the success of IO so far has
been limited. This volume of Delivery Strategies and Engineering
Technologies in Cancer Immunotherapy discusses biomaterial,
microfluidic, and biodegradable devices, engineered microbes,
personalized medicine, clinical approval process, and many other IO
technologies. Engineering Technologies and Clinical Translation:
Volume 3: Delivery Strategies and Engineering Technologies in
Cancer Immunotherapy creates a comprehensive treaty that engages
the scientific and medical community who are involved in the
challenges of immunology, cancer biology, and therapeutics with
possible solutions from the nanotechnology and drug delivery side.
Direct Nose-to-Brain Drug Delivery provides the reader with precise
knowledge about the strategies and approaches for enhanced
nose-to-brain drug delivery. It highlights the development of novel
nanocarrier-based drug delivery systems for targeted drug delivery
to the brain microenvironments with a focus on the technological
advances in the development of the novel drug delivery devices for
intranasal administration, including special emphasis on brain
targeting through nose. This book explores the various
quantification parameters to assess the brain targeting efficiency
following intranasal administration and includes an overview on the
toxicity aspects of the various materials used to develop the
direct nose-to-brain drug delivery vehicles and of the regulatory
aspects including patents and current clinical status of the
potential neurotherapeutics for the effective management of
neuro-ailments. Technological advances in new drug delivery systems
with diverse applications in pharmaceutical, biomedical,
biomaterials, and biotechnological fields are also explained. This
book is a crucial source that will assist the veteran scientists,
industrial technologists, and clinical research professionals to
develop new drug delivery systems and novel drug administration
devices for the treatment of neuro-ailments.
Reliable, precise and accurate detection and analysis of biomarkers
remains a significant challenge for clinical researchers. Methods
for the detection of biomarkers are rather complex, requiring
pre-treatment steps before analysis can take place. Moreover,
comparing various biomarker assays and tracing research progress in
this area systematically is a challenge for researchers. The
Detection of Biomarkers presents developments in biomarker
detection, including methods tools and strategies, biosensor
design, materials, and applications. The book presents methods,
materials and procedures that are simple, precise, sensitive,
selective, fast and economical, and therefore highly practical for
use in clinical research scenarios. This volume situates biomarker
detection in its research context and sets out future prospects for
the area. Its 20 chapters offer a comprehensive coverage of
biomarkers, including progress on nanotechnology, biosensor types,
synthesis, immobilization, and applications in various fields. The
book also demonstrates, for students, how to synthesize and
immobilize biosensors for biomarker assay. It offers researchers
real alternative and innovative ways to think about the field of
biomarker detection, increasing the reliability, precision and
accuracy of biomarker detection.
Brucella Miletensis: Identification and Characterization of
Potential Drug Targets presents a systematic approach to
identifying and characterizing drug targets using bioinformatics.
The book shows the potential of bioinformatic tools in the
identification of virulence targets in pathogenic bacteria and
viruses, in general, and in B. militensis 16M in particular.
Chapters identify putative genes as potential drug targets, employ
a subtractive genomic approach, consider the virulent genes of this
bacteria that negatively affects humans, list twelve potential
virulence genes as drug targets, and consider the screening of
potential drugs against the bacteria's virulence genes through
molecular modeling, computational screening, drug discovery and
molecular docking studies. In addition, the book demonstrates in
silico approaches that offer insights into the identification of
drug targets in B.melitensis 16M. The title employs a step-by-step
approach to understanding drug targets by identifying and
characterizing vaccine targets for Brucella melitensis, in silico
screening, and the identification of novel drug targets from the
total Brucella melitensis proteome. Other sections cover
computational modeling and evaluation of the best potential drug
targets through comparative modeling, molecular docking, and
dynamics simulations of novel drug targets and in silico validation
and ADMET analysis for best lead molecules.
Progress in molecular and cellular biology has greatly enhanced our
ability to accurately diagnose diseases that are caused by gene
mutations, changes in genome structures, and altered gene
expression; increased emphasis is now placed on translational
research the clinical treatment of these genetically determined
diseases. Seeking Cures outlines the progress and implications of
science's quest to identify therapeutic targets and initiate novel
treatments at the gene, RNA, protein, and physiological levels.
Also considered are aspects of treatment at the cellular level
(e.g., those with hematopoietic stem cells or induced pluripotent
stem cells). Topics covered in this text include: * outline of the
processes typical for identifying disease-modifying therapies *
examples of newer therapeutic approaches in use or under
investigation to treat lysosomal storage diseases, inborn errors of
metabolism, mitochondrial functional defects, and specific
monogenic diseases * therapeutic designs for specific complex
common diseases, including Alzheimer's disease, cancer, and autism
Through these specific examples, Seeking Cures provides a glimpse
at the pursuit-and future-of personalized medicine.
|
|